Exagen (NASDAQ:XGN) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 15 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $17.306 million which beat the analyst consensus estimate of $16.414 million by 5.43 percent. This is a 11.67 percent increase over sales of $15.498 million the same period last year.